Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial

Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial

Carrimycin is a potential immune-regulating agent for sepsis in patients with tumors. In this study, we investigated its effects on inflammation and immune function in tumor patients with sepsis. In total, 120 participants were randomized to receive either carrimycin treatment (400 mg/day) (n = 62)...

Full description

Bibliographic Details
Main Authors: Chuanchuan Nan, Xiaowu Zhang, Wei Huang, Biao Zhu, Jianghong Zhao, Song Lu, Lewu Xian, Kaizhong Liu, Gang Ma, Wei Yang, Mingguang Huang, Dongmin Zhou, Ming Zhang, Yan Duan, Guixin Wu, Zhengying Jiang, Li Zhang, Xinrong He, Yuhong Chen, Xuezhong Xing, Changsong Wang, Donghao Wang, Kaijiang Yu
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Pharmacological Research
Subjects:
Carrimycin
CD8+ T cells
HLA-DR
Immune
Sepsis
Tumor
Online Access:http://www.sciencedirect.com/science/article/pii/S104366182300347X

Internet

http://www.sciencedirect.com/science/article/pii/S104366182300347X

Similar Items